These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38696125)

  • 1. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.
    Losa M; Mazza E; Pedone E; Nocera G; Liscia N; Reni M; Mortini P
    J Endocrinol Invest; 2024 Nov; 47(11):2835-2842. PubMed ID: 38696125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
    Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
    Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
    Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
    Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES
    J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
    Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
    Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
    Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
    CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
    Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
    Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
    Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study.
    De Alcubierre D; Gkasdaris G; Mordrel M; Joncour A; Briet C; Almairac F; Boetto J; Mouly C; Larrieu-Ciron D; Vasiljevic A; Villa C; Sergeant C; Ducray F; Feuvret L; Chanson P; Baussart B; Raverot G; Jouanneau E
    Eur J Endocrinol; 2024 Aug; 191(2):251-261. PubMed ID: 39158090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
    Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
    World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
    Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
    Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
    Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
    Brastianos PK; Twohy E; Geyer S; Gerstner ER; Kaufmann TJ; Tabrizi S; Kabat B; Thierauf J; Ruff MW; Bota DA; Reardon DA; Cohen AL; De La Fuente MI; Lesser GJ; Campian J; Agarwalla PK; Kumthekar P; Mann B; Vora S; Knopp M; Iafrate AJ; Curry WT; Cahill DP; Shih HA; Brown PD; Santagata S; Barker FG; Galanis E
    N Engl J Med; 2023 Jul; 389(2):118-126. PubMed ID: 37437144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
    Gritsch D; Santagata S; Brastianos PK
    Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
    Sidaway P
    Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
    [No Abstract]   [Full Text] [Related]  

  • 17. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
    Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecularly Targeted Therapy for Craniopharyngioma].
    Tanaka S; Takayanagi S; Takami H; Saito N
    No Shinkei Geka; 2022 Jan; 50(1):171-178. PubMed ID: 35169097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 20. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
    Brastianos PK; Santagata S
    Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.